Glyco-Therapeutics

Glycans on the therapeutic glycoproteins are known to affect the product's stability, PK/PD, and activity. For example, N-glycans on human IgG have important roles in modulating its secretion as well as the effector functions through antibody-dependent cellular cytotoxicity (ADCC), and this discovery has led to the development of several new cancer therapeutic antibodies with improved efficacy.

With the emergence of the precise gene editing technologies it is now possible to perform comprehensive glycoengineering on glycoprotein therapeutics produced in mammalian cells, and GlycoDisplay has developed extensive design strategies for novel glycans on therapeutic glycoproteins. With GlycoDisplay's glycoengineering technology we can design and express optimal glycan structures on preferred proteins, offering our customers to effectively develop novel glycoengineered biologics.

Examples of glycoengineered biologics GlycoDisplay has worked include EPO with homogeneous glycans, IgG with homogeneous glycans, and lysosomal replacement enzymes with extended half-life.